TBRA

Tobira Therapeutics Inc

A clinical-stage biopharmaceutical company that developed therapies for non-alcoholic steatohepatitis (NASH), a serious liver disease, and other inflammatory conditions. Founded in 2007 by Dr. Eckard Weber in South San Francisco, it began with HIV drugs licensed from Takeda before pivoting to liver disease and going public through a 2015 reverse merger with Regado Biosciences. Its name comes from the Japanese word for "door," chosen to symbolize opening new paths in medicine.

No proxy statement recorded.